Clinical Trial Update: Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y [Phase 2]

View source ↗

Summary

This Phase 2 study assesses immunogenicity and safety of various HBV-MPL vaccine formulations compared with Engerix-B in adults aged 18-40; the trial status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Engerix-B (hepatitis B vaccine)
• HBV-MPL vaccine formulations (HBV vaccine with MPL adjuvant)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B | Phase 2 | Status: COMPLETED